Elan Corp. Faces Valuation Adjustment Amidst Mixed Financial Performance and Market Underperformance

Elan Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation. This revision reflects a shift in its valuation grade from a previously noted level to a fair assessment. Key financial metrics indicate that Elan Corp. maintains a P/E ratio of 16, alongside a Price to Book Value of 3.09. The company's EV to EBIT stands at 9.03, while its EV to EBITDA is recorded at 6.86. Additionally, the EV to Sales ratio is 0.70, and the PEG ratio is noted at 0.79. Despite these metrics, the company has faced challenges, including a negative financial performance reported for the quarter ending December 2025. The interest coverage ratio is at a notably low level of 5,598.83, and the dividend payout ratio is also low at 121.74%. Inventory turnover has been recorded at 16.57 times, indicating a need for improvement in operational efficiency. Elan Corp. has demonstrated strong long-term fundamental strength, with an average Return on Equity (ROE) of 19.58% and a healthy growth rate in net sales and operating profit. However, the stock has underperformed relative to the broader market, generating a return of 3.97% over the past year, significantly lower than the Japan Nikkei 225's returns of 63.26%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.